T. Rowe Price Associates’s Edgewise Therapeutics EWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $665K | Sell |
50,682
-244,199
| -83% | -$3.2M | ﹤0.01% | 2166 |
|
|
2025
Q1 | $6.49M | Buy |
294,881
+265,831
| +915% | +$5.85M | ﹤0.01% | 1201 |
|
|
2024
Q4 | $776K | Buy |
29,050
+5,242
| +22% | +$140K | ﹤0.01% | 2073 |
|
|
2024
Q3 | $636K | Buy |
23,808
+722
| +3% | +$19.3K | ﹤0.01% | 2162 |
|
|
2024
Q2 | $416K | Buy |
23,086
+6,662
| +41% | +$120K | ﹤0.01% | 2265 |
|
|
2024
Q1 | $300K | Sell |
16,424
-109,647
| -87% | -$2M | ﹤0.01% | 2433 |
|
|
2023
Q4 | $1.38M | Buy |
126,071
+367
| +0.3% | +$4.02K | ﹤0.01% | 1711 |
|
|
2023
Q3 | $722K | Buy |
125,704
+1,024
| +0.8% | +$5.88K | ﹤0.01% | 1943 |
|
|
2023
Q2 | $968K | Buy |
124,680
+2,110
| +2% | +$16.4K | ﹤0.01% | 1823 |
|
|
2023
Q1 | $819K | Sell |
122,570
-135,756
| -53% | -$907K | ﹤0.01% | 1882 |
|
|
2022
Q4 | $2.31M | Buy |
258,326
+2,088
| +0.8% | +$18.7K | ﹤0.01% | 1417 |
|
|
2022
Q3 | $2.52M | Sell |
256,238
-92,985
| -27% | -$915K | ﹤0.01% | 1369 |
|
|
2022
Q2 | $2.78M | Sell |
349,223
-552
| -0.2% | -$4.39K | ﹤0.01% | 1523 |
|
|
2022
Q1 | $3.39M | Buy |
+349,775
| New | +$3.39M | ﹤0.01% | 1540 |
|